Spectral Diagnostics Inc. Today Announces Completion of Special Pricing Arrangements Through Cardinal Health Distribution Agreements with Three Large Group Purchasing Organizations

Business Wire, Nov 16, 2004

TORONTO -- Spectral Diagnostics Inc. (TSX:SDI), today announces the completion of three pricing agreements through Cardinal Health distribution agreements with three large Group Purchasing Organizations (GPO's) in the United States.

Through Spectral's exclusive distribution agreement with Cardinal Health, Spectral now has "courtesy ceiling pricing" in place with three of the largest GPO's in the United States. Novation, Med Assets and Amerinet now have pricing arrangements and additional incentives to implement Spectral's Chest Pain Management products within their member hospitals. Spectral's cardiac line offers a proven tool to assist in the rapid risk stratification of patients with chest pain.

Novation has relationships with over 2,300 healthcare facilities representing over 90,000 staffed beds, while Amerinet includes over 1,800 healthcare facilities in its active GPO membership. Med Assets serves over 13,000 healthcare facilities nationwide.

"By having specific relationships with these three major GPO's in the United States, Spectral's cardiac product line becomes competitive and much more widely available. This opportunity is available to Spectral only because of its exclusive Distribution Agreement with Cardinal Health," stated Dr. Paul Walker, President and CEO of Spectral.

Spectral is a developer of innovative technologies for comprehensive disease management. Spectral provides accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Current products are rapid format tests measuring markers of myocardial infarction (Cardiac STATus(R)). New products include rapid diagnostics for sepsis (the Endotoxin Activity Assay). Spectral manufactures the EAA and Cardiac STATus(R). Spectral's common shares are listed on The Toronto Stock Exchange: SDI.

This press release contains certain forward-looking statements and information based on beliefs of the Company's senior management as well as assumptions made by, and information currently available to it. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

SEDAR Filer Profile Number: 00002006

Spectral Diagnostics Inc. (TSX:SDI)